Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
Clinical trial NCT01775124 · COMPLETED
Trial details
- NCT number
- NCT01775124
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2013-02-22
- Primary completion
- 2015-11-23
- Enrollment
- 332
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.